Yasaman Aghazadeh1,2, Maria Cristina Nostro3,4,5. 1. Toronto General Hospital Research Institute and McEwen Centre for Regenerative Medicine, Toronto, Canada. 2. University Health Network, Toronto, Ontario, M5G 1L7, Canada. 3. Toronto General Hospital Research Institute and McEwen Centre for Regenerative Medicine, Toronto, Canada. cnostro@uhnresearch.ca. 4. University Health Network, Toronto, Ontario, M5G 1L7, Canada. cnostro@uhnresearch.ca. 5. Department of Physiology, University of Toronto, Toronto, Ontario, M5S 1A8, Canada. cnostro@uhnresearch.ca.
Abstract
PURPOSE OF THE REVIEW: Type 1 diabetes (T1D) is defined by an autoimmune destruction of insulin producing β-cells located in the endocrine part of the pancreas, the islets of Langerhans. As exogenous insulin administration fails at preventing severe complications associated with this disease, cell replacement therapies are being considered as a means to treat T1D. The purpose of this manuscript is to review the challenges associated with current strategies and discuss the potential of stem cell therapy for the treatment of T1D. RECENT FINDINGS: The most prominent therapy offered to T1D patients is exogenous insulin administration which, despite formulations improvement, remains a suboptimal treatment, due to the frequency of injections and the issues associated with precise dosing. As immunotherapy approaches have remained unsuccessful, the only cure for T1D is transplantation of donor-derived pancreas or islets. However, donor scarcity, graft loss, and immune response to the foreign tissue are issues challenging this approach and limiting the number of patients who can benefit from such treatments. In this review, we discuss the causes of T1D and the shortcomings of the current treatments. Furthermore, we summarize the cutting edge research that aims to tackle the current challenges in reaching a quality-controlled product with long-term effects, with a focus on regenerative medicine approaches using human pluripotent stem cells.
PURPOSE OF THE REVIEW: Type 1 diabetes (T1D) is defined by an autoimmune destruction of insulin producing β-cells located in the endocrine part of the pancreas, the islets of Langerhans. As exogenous insulin administration fails at preventing severe complications associated with this disease, cell replacement therapies are being considered as a means to treat T1D. The purpose of this manuscript is to review the challenges associated with current strategies and discuss the potential of stem cell therapy for the treatment of T1D. RECENT FINDINGS: The most prominent therapy offered to T1D patients is exogenous insulin administration which, despite formulations improvement, remains a suboptimal treatment, due to the frequency of injections and the issues associated with precise dosing. As immunotherapy approaches have remained unsuccessful, the only cure for T1D is transplantation of donor-derived pancreas or islets. However, donor scarcity, graft loss, and immune response to the foreign tissue are issues challenging this approach and limiting the number of patients who can benefit from such treatments. In this review, we discuss the causes of T1D and the shortcomings of the current treatments. Furthermore, we summarize the cutting edge research that aims to tackle the current challenges in reaching a quality-controlled product with long-term effects, with a focus on regenerative medicine approaches using human pluripotent stem cells.
Authors: Kevin A D'Amour; Alan D Agulnick; Susan Eliazer; Olivia G Kelly; Evert Kroon; Emmanuel E Baetge Journal: Nat Biotechnol Date: 2005-10-28 Impact factor: 54.908
Authors: Shuibing Chen; Malgorzata Borowiak; Julia L Fox; René Maehr; Kenji Osafune; Lance Davidow; Kelvin Lam; Lee F Peng; Stuart L Schreiber; Lee L Rubin; Douglas Melton Journal: Nat Chem Biol Date: 2009-03-15 Impact factor: 15.040
Authors: Jennifer Y C Cheng; Michael Raghunath; John Whitelock; Laura Poole-Warren Journal: Tissue Eng Part B Rev Date: 2011-05-25 Impact factor: 6.389
Authors: M Sander; L Sussel; J Conners; D Scheel; J Kalamaras; F Dela Cruz; V Schwitzgebel; A Hayes-Jordan; M German Journal: Development Date: 2000-12 Impact factor: 6.868
Authors: Laura M Jacobsen; Brittney N Newby; Daniel J Perry; Amanda L Posgai; Michael J Haller; Todd M Brusko Journal: Curr Diab Rep Date: 2018-08-30 Impact factor: 4.810
Authors: Hedi L Claahsen-van der Grinten; Phyllis W Speiser; S Faisal Ahmed; Wiebke Arlt; Richard J Auchus; Henrik Falhammar; Christa E Flück; Leonardo Guasti; Angela Huebner; Barbara B M Kortmann; Nils Krone; Deborah P Merke; Walter L Miller; Anna Nordenström; Nicole Reisch; David E Sandberg; Nike M M L Stikkelbroeck; Philippe Touraine; Agustini Utari; Stefan A Wudy; Perrin C White Journal: Endocr Rev Date: 2022-01-12 Impact factor: 19.871
Authors: Giulia Donadel; Donatella Pastore; David Della-Morte; Barbara Capuani; Marco F Lombardo; Francesca Pacifici; Marco Bugliani; Fabio A Grieco; Piero Marchetti; Davide Lauro Journal: Int J Mol Sci Date: 2017-10-25 Impact factor: 5.923
Authors: Adebola Matthew Giwa; Rizwan Ahmed; Zahra Omidian; Neha Majety; Kagan Ege Karakus; Sarah M Omer; Thomas Donner; Abdel Rahim A Hamad Journal: World J Diabetes Date: 2020-01-15
Authors: Charles-Henri Wassmer; Fanny Lebreton; Kevin Bellofatto; Lisa Perez; David Cottet-Dumoulin; Axel Andres; Domenico Bosco; Thierry Berney; Véronique Othenin-Girard; Begoña Martinez De Tejada; Marie Cohen; Christina Olgasi; Antonia Follenzi; Ekaterine Berishvili Journal: Transpl Int Date: 2022-01-21 Impact factor: 3.842